KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Enterprise Value (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Enterprise Value data on record, last reported at -$215.8 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 31175.22% year-over-year to -$215.8 million; the TTM value through Sep 2025 reached -$298.7 million, down 282.98%, while the annual FY2025 figure was -$215.8 million, 31175.22% down from the prior year.
  • Enterprise Value reached -$215.8 million in Q4 2025 per PACB's latest filing, up from -$298.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$690000.0 in Q4 2024 and bottomed at -$1.0 billion in Q4 2021.
  • Average Enterprise Value over 5 years is -$411.2 million, with a median of -$320.1 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: surged 99.89% in 2024, then plummeted 31175.22% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$1.0 billion in 2021, then skyrocketed by 68.84% to -$325.4 million in 2022, then crashed by 94.05% to -$631.4 million in 2023, then soared by 99.89% to -$690000.0 in 2024, then tumbled by 31175.22% to -$215.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$215.8 million in Q4 2025, -$298.7 million in Q3 2025, and -$314.7 million in Q2 2025.